Lilly asks FDA for emergency clearance for COVID-19 antibody therapyEli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing Share XLilly asks FDA for emergency clearance for COVID-19 antibody therapyhttps://pharmaphorum.com/news/lilly-asks-fda-for-emergency-clearance-for-covid-19-antibody-therapy/
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalGlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting Share XGSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalhttps://pharmaphorum.com/news/gsk-and-vir-expand-covid-19-antibody-trial-after-trumps-treatment-with-regenerons-rival/
AZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than Share XAZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’https://pharmaphorum.com/news/az-halts-covid-19-vaccine-after-safety-scare-as-uk-faces-second-wave/
Sanofi and GSK begin clinical trials of coronavirus vaccineSanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival Share XSanofi and GSK begin clinical trials of coronavirus vaccinehttps://pharmaphorum.com/news/sanofi-and-gsk-begin-clinical-trials-of/
GSK opens £10m AI hub in LondonGlaxoSmithKline is opening a £10 million artificial intelligence (AI) research hub in King’s Cross, London, according to a Share XGSK opens £10m AI hub in Londonhttps://pharmaphorum.com/news/gsk-opens-10m-ai-hub-in-london/
GSK and Vir take COVID-19 antibody therapy into clinicGlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed Share XGSK and Vir take COVID-19 antibody therapy into clinichttps://pharmaphorum.com/news/gsk-and-vir-take-covid-19-antibody-therapy-into-clinic/
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a Share XIonis deal delivers for GSK as HBV drug hits the mark in phase 2https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/
GSK moves further ahead in BCMA with EU okay for BlenrepGlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the Share XGSK moves further ahead in BCMA with EU okay for Blenrephttps://pharmaphorum.com/news/gsk-moves-further-ahead-in-bcma-with-eu-okay-for-blenrep/
US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccineThe US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 Share XUS pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccinehttps://pharmaphorum.com/news/us-pays-sanofi-gsk-100-million-doses-covid-19-vaccine/
